ribociclib
novartis
['bcsm']
primary endpoint of maintain was pfs. 119 participants randomized. pfs at 6 months 41.2% in ribo+et arm versus 22.9% in placebo+et arm and nearly tripled at 12 months. most patients received fulvestrant as their et. #bcsm #asco22
Breast & gyn med onc @valleyhospital in NJ. Focus on survivorship and ?????? onc. All opinions my own. Retweets not endorsements. Host of INTERLUDE podcast ??